Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 15657177 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Zheng Y, et al. (2005) Phosphorylation of RasGRP3 on threonine 133 provides a mechanistic link between PKC and Ras signaling systems in B cells. Blood 105, 3648-54 15657177
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T202-p - ERK1 (human) ▲
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  lymphoma, Burkitt's lymphoma
 Relevant cell lines - cell types - tissues:  RAMOS (B lymphocyte), Rat2 (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human, rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anti-IgM increase
Ro31-8220 anti-IgM inhibit treatment-induced increase
Go 6976 anti-IgM inhibit treatment-induced increase
phorbol ester increase
Ro31-8220 phorbol ester inhibit treatment-induced increase
Go 6976 phorbol ester no effect upon treatment-induced increase
anti-CD3 increase
Ro31-8220 anti-CD3 inhibit treatment-induced increase
Go 6976 anti-CD3 inhibit treatment-induced increase

Y204-p - ERK1 (human) ▲
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  lymphoma, Burkitt's lymphoma
 Relevant cell lines - cell types - tissues:  RAMOS (B lymphocyte), Rat2 (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human, rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anti-IgM increase
Ro31-8220 anti-IgM inhibit treatment-induced increase
Go 6976 anti-IgM inhibit treatment-induced increase
phorbol ester increase
Ro31-8220 phorbol ester inhibit treatment-induced increase
Go 6976 phorbol ester no effect upon treatment-induced increase
anti-CD3 increase
Ro31-8220 anti-CD3 inhibit treatment-induced increase
Go 6976 anti-CD3 inhibit treatment-induced increase

T185-p - ERK2 (human) ▲
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  lymphoma, Burkitt's lymphoma
 Relevant cell lines - cell types - tissues:  RAMOS (B lymphocyte), Rat2 (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human, rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anti-IgM increase
Ro31-8220 anti-IgM inhibit treatment-induced increase
Go 6976 anti-IgM inhibit treatment-induced increase
phorbol ester increase
Ro31-8220 phorbol ester inhibit treatment-induced increase
Go 6976 phorbol ester no effect upon treatment-induced increase
anti-CD3 increase
Ro31-8220 anti-CD3 inhibit treatment-induced increase
Go 6976 anti-CD3 inhibit treatment-induced increase

Y187-p - ERK2 (human) ▲
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  lymphoma, Burkitt's lymphoma
 Relevant cell lines - cell types - tissues:  RAMOS (B lymphocyte), Rat2 (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human, rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anti-IgM increase
Ro31-8220 anti-IgM inhibit treatment-induced increase
Go 6976 anti-IgM inhibit treatment-induced increase
phorbol ester increase
Ro31-8220 phorbol ester inhibit treatment-induced increase
Go 6976 phorbol ester no effect upon treatment-induced increase
anti-CD3 increase
Ro31-8220 anti-CD3 inhibit treatment-induced increase
Go 6976 anti-CD3 inhibit treatment-induced increase

T184-p - RasGRP1 (human) ▲
Orthologous residues
RasGRP1 (human): T184‑p, RasGRP1 (mouse): T184‑p, RasGRP1 (rat): T184‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  Jurkat (T lymphocyte), Rat2 (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human, rat
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PKCT (human) pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anti-CD3 increase
Ro31-8220 anti-CD3 inhibit treatment-induced increase
Go 6976 anti-CD3 inhibit treatment-induced increase
phorbol ester increase

T133-p - RasGRP3 (human) ▲
Orthologous residues
RasGRP3 (human): T133‑p, RasGRP3 (mouse): T133‑p, RasGRP3 (rat): T133‑p, RasGRP3 (chicken): T133‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  lymphoma, Burkitt's lymphoma
 Relevant cell lines - cell types - tissues:  RAMOS (B lymphocyte), Rat2 (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human, rat
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE PKCT (human)
KINASE PKCD (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PKCT (human) pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anti-IgM increase
Ro31-8220 anti-IgM inhibit treatment-induced increase
Go 6976 anti-IgM inhibit treatment-induced increase
phorbol ester increase
Ro31-8220 phorbol ester inhibit treatment-induced increase
Go 6976 phorbol ester no effect upon treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.